Veröffentlichungen

Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer

Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.

Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria

Filename 414. Kolkhir et al., Autoimmune Type IIb CSU, AAIR 2021.pdf
Filesize 1,94 MB
Version o.414
Date added Mai 31, 2021
Downloaded 3 times
Category Original Work
Tags Autoantibodies, autoimmune diseases, autoimmune thyroiditis, autoimmunity, Chronic Urticaria, immunoassay, omalizumab, vitiligo
Authors Kolkhir, P., Altrichter, S., Asero, R., Daschner, A., Ferrer, M., Giménez-Arnau, A., Hawro, T., Jakob, T., Kinaciyan, T., Kromminga, A., Konstantinou, G. N. Makris, M., Metz, M., Stahl Skov, P., Staubach, P., Sussman, G., Zhang, K., and Maurer, M.
Citation Kolkhir, P., Altrichter, S., Asero, R., Daschner, A., Ferrer, M., Giménez-Arnau, A., Hawro, T., Jakob, T., Kinaciyan, T., Kromminga, A., Konstantinou, G. N. Makris, M., Metz, M., Stahl Skov, P., Staubach, P., Sussman, G., Zhang, K., and Maurer, M.: Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 2021: 13; 545-559.
Corresponding authors Maurer, M.
DocNum o.414
DocType PDF
IF 5.10
Publisher Allergy Asthma Immunol. Res.
ReleaseDate 2021

Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid autoimmune diseases.
Methods: We analyzed records of CSU patients (n = 1,199) for a history or presence of autoimmune diseases. Patients were diagnosed with type IIb autoimmune CSU (aiCSU) if all 3 tests were positive: autologous serum skin test (ASST), basophil histamine release assay (BHRA) and/or basophil activation test (BAT), and IgG autoantibodies against FcεRIα/IgE detected by immunoassay.
Results: Twenty-eight percent of CSU patients had at least 1 autoimmune disease. The most prevalent autoimmune diseases were Hashimoto’s thyroiditis (HT) (≥ 21%) and vitiligo (2%). Two percent of CSU patients had ≥ 2 autoimmune diseases, most frequently HT plus vitiligo. Comorbid autoimmune diseases, in patients with CSU, were associated with female sex, a family history of autoimmune diseases, and higher rates of hypothyroidism and hyperthyroidism (P < 0.001). Presence of autoimmune diseases was linked to aiCSU (P = 0.02). The risks of having autoimmune diseases were 1.7, 2.9 and 3.3 times higher for CSU patients with a positive ASST, BHRA and BAT, respectively. In CSU patients, markers for autoimmune diseases, antinuclear antibodies and/or IgG anti-thyroid antibodies were associated with non-response to omalizumab treatment (P = 0.013).
Conclusions: In CSU, autoimmune diseases are common and linked to type IIb autoimmune CSU. Our results suggest that physicians assess and monitor all adult patients with CSU for signs and symptoms of common autoimmune diseases, especially HT and vitiligo.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.